drugset / Trial / NCT01769209
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the value of bortezomib in combination with specified chemotherapies for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2013-03
- Primary completion
- 2016-11-25
- Completion
- 2017-07-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Background | Cytarabine | Small molecule | 100 mg | Intrathecal |
| Background | Dexamethasone | Small molecule | 10 mg/m2 | Oral |
| Background | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Background | Methotrexate | Small molecule | 15 mg | Intrathecal |
| Background | Pegaspargase | Protein / enzyme biologic | 2500 unknown | Intravenous |
| Background | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |